CA3094891A1 - Cyclosporine formulations for use in the treatment of bronchiolitis obliterans syndrome (bos) - Google Patents
Cyclosporine formulations for use in the treatment of bronchiolitis obliterans syndrome (bos) Download PDFInfo
- Publication number
- CA3094891A1 CA3094891A1 CA3094891A CA3094891A CA3094891A1 CA 3094891 A1 CA3094891 A1 CA 3094891A1 CA 3094891 A CA3094891 A CA 3094891A CA 3094891 A CA3094891 A CA 3094891A CA 3094891 A1 CA3094891 A1 CA 3094891A1
- Authority
- CA
- Canada
- Prior art keywords
- bos
- composition
- patient
- csa
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dispersion Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Otolaryngology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862656226P | 2018-04-11 | 2018-04-11 | |
| US62/656,226 | 2018-04-11 | ||
| EP18172067 | 2018-05-14 | ||
| EP18172067.3 | 2018-05-14 | ||
| PCT/EP2019/058958 WO2019197406A1 (en) | 2018-04-11 | 2019-04-09 | Cyclosporine formulations for use in the treatment of bronchiolitis obliterans syndrome (bos) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3094891A1 true CA3094891A1 (en) | 2019-10-17 |
Family
ID=66049232
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3094891A Pending CA3094891A1 (en) | 2018-04-11 | 2019-04-09 | Cyclosporine formulations for use in the treatment of bronchiolitis obliterans syndrome (bos) |
Country Status (21)
| Country | Link |
|---|---|
| US (4) | US11484566B2 (https=) |
| EP (2) | EP4400119A3 (https=) |
| JP (2) | JP2021520396A (https=) |
| CN (1) | CN112105374A (https=) |
| AU (1) | AU2019253137B2 (https=) |
| BR (1) | BR112020020564A2 (https=) |
| CA (1) | CA3094891A1 (https=) |
| CO (1) | CO2020013427A2 (https=) |
| DK (1) | DK3773664T3 (https=) |
| ES (1) | ES2980198T3 (https=) |
| FI (1) | FI3773664T3 (https=) |
| HR (1) | HRP20241022T1 (https=) |
| HU (1) | HUE067518T2 (https=) |
| IL (1) | IL277253B2 (https=) |
| LT (1) | LT3773664T (https=) |
| MX (1) | MX2020010738A (https=) |
| PL (1) | PL3773664T3 (https=) |
| RS (1) | RS65713B1 (https=) |
| SI (1) | SI3773664T1 (https=) |
| SM (1) | SMT202400220T1 (https=) |
| WO (1) | WO2019197406A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3069711A1 (en) * | 2015-03-16 | 2016-09-21 | PARI Pharma GmbH | Cyclosporine formulations for use in the prevention or treatment of pulmonary chronic graft rejection |
| HRP20241022T1 (hr) * | 2018-04-11 | 2024-11-08 | Breath Therapeutics Gmbh | Formulacije ciklosporina za upotrebu u liječenju sindroma bronchiolitis obliterans (bos) |
| US10736847B2 (en) | 2018-07-03 | 2020-08-11 | Becton, Dickinson And Company | Inverting device for liposome preparation by centrifugation |
| CN114642677A (zh) * | 2020-12-21 | 2022-06-21 | 上海凯屹医药科技有限公司 | 一种稳定的含有苦丁皂苷类化合物的液体药物组合物 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020006901A1 (en) * | 1999-02-05 | 2002-01-17 | Aldo T. Iacono | Use of aerosolized cyclosporine for prevention and treatment of pulmonary disease |
| JP2005508220A (ja) | 2001-10-24 | 2005-03-31 | パーリ・ゲーエムベーハー | 薬用組成物調製用具 |
| DE102006051512A1 (de) | 2005-12-06 | 2007-06-14 | Pari GmbH Spezialisten für effektive Inhalation | Pharmazeutische Medikamentenzusammensetzungen mit Cyclosporin |
| EP3069711A1 (en) | 2015-03-16 | 2016-09-21 | PARI Pharma GmbH | Cyclosporine formulations for use in the prevention or treatment of pulmonary chronic graft rejection |
| HRP20241022T1 (hr) * | 2018-04-11 | 2024-11-08 | Breath Therapeutics Gmbh | Formulacije ciklosporina za upotrebu u liječenju sindroma bronchiolitis obliterans (bos) |
-
2019
- 2019-04-09 HR HRP20241022TT patent/HRP20241022T1/hr unknown
- 2019-04-09 BR BR112020020564-8A patent/BR112020020564A2/pt unknown
- 2019-04-09 CA CA3094891A patent/CA3094891A1/en active Pending
- 2019-04-09 WO PCT/EP2019/058958 patent/WO2019197406A1/en not_active Ceased
- 2019-04-09 EP EP24172897.1A patent/EP4400119A3/en active Pending
- 2019-04-09 RS RS20240768A patent/RS65713B1/sr unknown
- 2019-04-09 IL IL277253A patent/IL277253B2/en unknown
- 2019-04-09 FI FIEP19715929.6T patent/FI3773664T3/fi active
- 2019-04-09 ES ES19715929T patent/ES2980198T3/es active Active
- 2019-04-09 US US17/046,307 patent/US11484566B2/en active Active
- 2019-04-09 MX MX2020010738A patent/MX2020010738A/es unknown
- 2019-04-09 LT LTEPPCT/EP2019/058958T patent/LT3773664T/lt unknown
- 2019-04-09 SI SI201930768T patent/SI3773664T1/sl unknown
- 2019-04-09 CN CN201980025434.8A patent/CN112105374A/zh active Pending
- 2019-04-09 HU HUE19715929A patent/HUE067518T2/hu unknown
- 2019-04-09 EP EP19715929.6A patent/EP3773664B1/en active Active
- 2019-04-09 AU AU2019253137A patent/AU2019253137B2/en active Active
- 2019-04-09 SM SM20240220T patent/SMT202400220T1/it unknown
- 2019-04-09 PL PL19715929.6T patent/PL3773664T3/pl unknown
- 2019-04-09 JP JP2020555145A patent/JP2021520396A/ja active Pending
- 2019-04-09 DK DK19715929.6T patent/DK3773664T3/da active
-
2020
- 2020-10-26 CO CONC2020/0013427A patent/CO2020013427A2/es unknown
-
2022
- 2022-09-26 US US17/935,140 patent/US11701403B2/en active Active
-
2023
- 2023-05-23 US US18/321,788 patent/US12178843B2/en active Active
-
2024
- 2024-03-07 JP JP2024035414A patent/JP2024069355A/ja active Pending
- 2024-11-26 US US18/959,730 patent/US20250090625A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12178843B2 (en) | Cyclosporine formulations for use in the treatment of bronchiolitis obliterans syndrome (BOS) | |
| US11744872B2 (en) | Cyclosporine formulations for use in the prevention or treatment of pulmonary chronic graft rejection | |
| JP6840869B2 (ja) | 肺障害の治療方法 | |
| KR20110074981A (ko) | 리포솜 아미카신 제형물로의 폐 장애 치료 방법 | |
| US20120213707A1 (en) | Riboflavin Based Aerosol and Use as Placebo in Trials | |
| EA047564B1 (ru) | Составы циклоспорина для применения для лечения синдрома облитерирующего бронхиолита (bos) | |
| JP7401471B2 (ja) | 凍結乾燥形態の医薬組成物 | |
| BR112017018339B1 (pt) | Uso de uma formulação líquida de ciclosporina | |
| HK40014607A (en) | Methods for treating lung disorders | |
| HK40014607B (en) | Methods for treating lung disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220921 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250401 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250516 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250605 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20251002 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20251203 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20251203 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD Year of fee payment: 7 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260331 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260331 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20260408 |